Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151…
Biotechnology
US, South San Francisco [HQ]
Cash Flow Statement
9 Sheets · From 2023 to 2015Configuration
In Million USD. Margins, Growth Rates In %
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||
| Operating Cash Flow (OCF) | -15.00 | -72.00 | -76.00 | 50.00 | -151.00 | 416.00 | -211.00 | -244.00 | -357.00 | |
| Operating Cash (Net) | -15.00 | -72.00 | -76.00 | 50.00 | -151.00 | 416.00 | -211.00 | -244.00 | -357.00 | |
| Accounts Receivable | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Accounts Payable | 1.00 | - - | - - | - - | 1.00 | -1.00 | 3.00 | 2.00 | 2.00 | |
|
Working Capital
|
- - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Change | - - | 4.00 | 3.00 | 62.00 | 4.00 | 288.00 | -20.00 | -24.00 | -289.00 | |
| Other WC | -1.00 | 4.00 | 3.00 | 63.00 | 3.00 | 290.00 | -24.00 | -26.00 | -292.00 | |
| Investing Activities | ||||||||||
| Used Cash (Net) | -3.00 | -219.00 | -41.00 | -287.00 | 147.00 | -623.00 | -21.00 | -141.00 | 249.00 | |
| Capital Expenditure | -3.00 | -6.00 | -2.00 | -3.00 | -17.00 | -3.00 | -8.00 | -17.00 | -12.00 | |
| Purchases of Investments | - - | -226.00 | -179.00 | -557.00 | -369.00 | -1,285.00 | -1,422.00 | -1,115.00 | -1,813.00 | |
| Sale/Maturity of Investment | - - | 14.00 | 141.00 | 273.00 | 535.00 | 665.00 | 1,409.00 | 991.00 | 2,075.00 | |
| Property, Plant, Equipment (P&PE) | -3.00 | -6.00 | -2.00 | -3.00 | -17.00 | -3.00 | -8.00 | -17.00 | -12.00 | |
| Acquisitions (Net) | - - | - - | - - | - - | -165.00 | 620.00 | 13.00 | 123.00 | -262.00 | |
| Other Investing Activities | - - | - - | - - | - - | 165.00 | -620.00 | -13.00 | -123.00 | 262.00 | |
| Financing Activities | ||||||||||
| Used Cash (Net) | -48.00 | -300.00 | -296.00 | -97.00 | -6.00 | -634.00 | -19.00 | -310.00 | -17.00 | |
| Debt Repayment | - - | - - | - - | - - | - - | -297.00 | -3.00 | -3.00 | - - | |
| Dividends Paid | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Common Stock
|
- - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Issued | - - | - - | 265.00 | - - | 6.00 | 614.00 | 19.00 | 296.00 | 17.00 | |
| Repurchased | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Financing Activities | 48.00 | 300.00 | 30.00 | 97.00 | 6.00 | 318.00 | 3.00 | 17.00 | 17.00 | |
| Cash Balances | ||||||||||
| Begin of Period | - - | 30.00 | 39.00 | 218.00 | 78.00 | 80.00 | 508.00 | 294.00 | 218.00 | |
| End of Period | 30.00 | 39.00 | 218.00 | 78.00 | 80.00 | 508.00 | 294.00 | 219.00 | 127.00 | |
| Change | 30.00 | 9.00 | 178.00 | -140.00 | 2.00 | 427.00 | -213.00 | -75.00 | -90.00 | |
| Non-Cash Balances | ||||||||||
| Depreciation and Amortization | - - | 1.00 | 3.00 | 7.00 | 7.00 | 8.00 | 8.00 | 10.00 | 16.00 | |
| Stock Based Compensation | - - | 2.00 | 4.00 | - - | 38.00 | 50.00 | 85.00 | 99.00 | 108.00 | |
| Other | - - | 5.00 | - - | -2.00 | - - | -2.00 | -2.00 | -4.00 | -45.00 | |
| Highlighted metrics | ||||||||||
| Free Cash Flow (FCF) | -18.00 | -78.00 | -79.00 | 46.00 | -169.00 | 413.00 | -219.00 | -262.00 | -370.00 | |
| Cash Conversion Cycle (CCC) | - - | - - | - - | - - | -4.00 | 4.00 | -301.00 | -387.00 | -203.00 | |
| Invested Capital | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Other Operating Inflows/Outflows
|
||||||||||
| Forex Effect on Cash | - - | - - | - - | - - | - - | - - | - - | - - | - - |